SLC5A2 and type 2 diabetes mellitus: Thus, evidence from these large-scale clinical studies show that SGLT2 inhibitors, as a new type of hypoglycemic drug, can significantly improve the cardiorenal outcomes of patients with T2DM in addition to hypoglycemia, achieving comprehensive benefits for the “sugar–heart–kidney” system.